Table 2. Retrospective studies of ARL... | American Society of Hematology

Table 2.

Retrospective studies of ARL outcomes before and after HAART

		HAART, no.			CR, %, HAART					Median OS, mo, HAART
Reference	Type and comments	No	Yes	No	Yes	P	No	Yes	P
Vaccher et al¹⁵	HAART: more neuropathy, anemia, fewer Ols	80	24	36	50	NS	7	NR	–
Navarro et al¹⁶	CHOP regimen, all systemic ARL in this series; 2 yr OS (previous report): 60% vs 22%	54	39	39	60	.019	NR	NR	–
Hoffmann et al¹⁷	CHOP regimen; HAART response associated with much better OS	142	61	48	71	.006	9	NR	–
Besson et al⁷	Mostly CHOP-like regimens; higher CD4 count at diagnosis after HAART	63	42	NR	NR		6.3	21.2	.004
Gerard et al¹⁴	Half of patients treated with intensive regimens; after HAART, fewer received dose-reduced regimens	131	115	55	69	.04	9.5	NR	< .001

		HAART, no.			CR, %, HAART					Median OS, mo, HAART
Reference	Type and comments	No	Yes	No	Yes	P	No	Yes	P
Vaccher et al¹⁵	HAART: more neuropathy, anemia, fewer Ols	80	24	36	50	NS	7	NR	–
Navarro et al¹⁶	CHOP regimen, all systemic ARL in this series; 2 yr OS (previous report): 60% vs 22%	54	39	39	60	.019	NR	NR	–
Hoffmann et al¹⁷	CHOP regimen; HAART response associated with much better OS	142	61	48	71	.006	9	NR	–
Besson et al⁷	Mostly CHOP-like regimens; higher CD4 count at diagnosis after HAART	63	42	NR	NR		6.3	21.2	.004
Gerard et al¹⁴	Half of patients treated with intensive regimens; after HAART, fewer received dose-reduced regimens	131	115	55	69	.04	9.5	NR	< .001

NS indicates not significant; NR, not reported; and –, not calculated.